Compare
MaxCyte, Inc. vs OmniAb, Inc. vs Foxo Technologies Inc. vs NRC Health
| Latest fiscal year | MaxCyte, Inc. MXCT | OmniAb, Inc. OABI | Foxo Technologies Inc. FOXO | NRC Health NRC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $33.03M | $18.67M | $16.37M | $137.39M |
| Revenue growth (YoY) | -14.5% | -29.3% | +304.0% | -4.0% |
| Gross margin | 81.2% | n/a | n/a | n/a |
| Operating margin | -157.1% | -369.5% | -63.1% | 16.4% |
| Net margin | -135.1% | -347.0% | -75.9% | 8.4% |
| Net income | -$44.63M | -$64.78M | -$12.43M | $11.60M |
| EPS (Diluted) | -$0.42 | -$0.57 | n/a | $50.00 |
| Operating cash flow | -$34.41M | -$36.45M | -$3.87M | $26.45M |
| Free cash flow | -$36.18M | -$37.02M | -$3.93M | $15.74M |
| Cash & equivalents | $20.07M | $25.52M | $207.5K | $4.14M |
| Total assets | $202.51M | $300.91M | $44.58M | $134.88M |
| Total liabilities | $31.02M | $33.89M | $33.50M | $120.89M |
| Shareholders' equity | $171.49M | $267.03M | $11.14M | $13.99M |
| Return on year-end equity | -26.0% | -24.3% | -111.5% | 82.9% |
| Shares outstanding | 106.79M | 144.31M | n/a | 22.64M |
Revenue, most recent five fiscal years
| Fiscal year | MaxCyte, Inc. | OmniAb, Inc. | Foxo Technologies Inc. | NRC Health |
|---|---|---|---|---|
| Latest | $33.03M Ended 2025-12-31 | $18.67M Ended 2025-12-31 | $16.37M Ended 2025-12-31 | $137.39M Ended 2025-12-31 |
| 1 year earlier | $38.63M Ended 2024-12-31 | $26.39M Ended 2024-12-31 | $4.05M Ended 2024-12-31 | $143.06M Ended 2024-12-31 |
| 2 years earlier | $41.29M Ended 2023-12-31 | $34.16M Ended 2023-12-31 | $145.3K Ended 2023-12-31 | $148.58M Ended 2023-12-31 |
| 3 years earlier | $44.26M Ended 2022-12-31 | $59.08M Ended 2022-12-31 | $511.0K Ended 2022-12-31 | $151.57M Ended 2022-12-31 |
| 4 years earlier | $33.89M Ended 2021-12-31 | $34.75M Ended 2021-12-31 | $120.0K Ended 2021-12-31 | $147.95M Ended 2021-12-31 |